Key metabolic pathways were blocked using representative inhibitors in a macrophage and humanized aggressive B cell lymphoma (hMB; cell line information see STAR Methods) co-culture-assay system, and phagocytosis was assessed through specific antibody targeting (alemtuzumab; anti-CD52) (Figure 1A). Here, CD52 is linked to B-cell non-Hodgkin lymphoma.